| Assessment Status | Rapid Review Complete |
| HTA ID | 25056 |
| Drug | Inavolisib |
| Brand | Itovebi® |
| Indication | Inavolisib, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. |
| Assessment Process | |
| Rapid review commissioned | 02/09/2025 |
| Rapid review completed | 06/10/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inavolisib compared with the current standard of care. |